B. Riley Financial Varied
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

S&P Biotech SPDR (NY: XBI )

89.39 +0.80 (+0.90%)
Official Closing Price Updated: 8:00 PM EST, Jan 27, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 7,826,620
Open 88.56
Bid (Size) 89.23 (20)
Ask (Size) 89.39 (28)
Prev. Close 88.59
Today's Range 88.39 - 90.01
52wk Range 61.78 - 99.16
Shares Outstanding 909,500
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
2 ETFs That Can Set You Up for Life
Simplifying your investment strategy can help minimize your risk while still allowing you to earn some great returns. 
Via The Motley Fool
Healthcare Sector Is Lagging As We Enter 2022 Earnings Season
The healthcare sector is perceived as defensive but in 2023 there is more investor appetite for risk based on the QQQ comeback and the XBI strength. 
Via Talk Markets

Performance

YTD
+9.64%
+9.64%
1 Month
+13.40%
+13.40%
3 Month
+6.72%
+6.72%
6 Month
+10.18%
+10.18%
1 Year
+4.54%
+4.54%

More News

Read More
The Fed Should Stop Right Now
Via Talk Markets
J.P.Morgan Healthcare Conference JPM23: Biotech Rally Favors Smaller Caps
Via Talk Markets
Nice Gains During JPM23 Week: Benign CPI Report Brings Hope For A “Soft Landing”
Via Talk Markets
3 Unstoppable ETFs to Stock Up On in 2023
Via The Motley Fool
ETFs To Buy For 2023 After S&P 500's Worst Year Since 2008
Via Talk Markets
CRISPR, Genetics And AI — Why 2023 Could Be The Year For Biotech Stocks
Via Investor's Business Daily
5 Top Stocks for January
Via The Motley Fool
The Year In Review And Ahead
Via Talk Markets
Biogen's 2nd Alzheimer's Antibody, BeiGene's Cancer Drug Label Expansion, Adcom Test For Regeneron And More: January PDUFA Catalysts For Biotech Investors
Via Benzinga
2 Top Biotech Stocks to Buy for the Long Haul
Via The Motley Fool
Tuesday Talk: Where is Santa?
Via Talk Markets
Healthcare Portfolio Is Doing Well But Biotech Stocks Are Mired In Macro
Via Talk Markets
The 7 Hottest Biotech Stocks to Own in 2023 and Beyond
Via InvestorPlace
Mirati Plays Catch-Up With Amgen, Gilead's 2nd Try With AIDS Drug, Cytokinetics' Adcom Test And More: Key Nov FDA Decisions For Biotech Investors
Via Benzinga
Uncertainty Grips Markets-On A Clear Day Maybe You Can See A Week Ahead
Via Talk Markets
The 10 Most Shorted ETFs: Which Sectors Saw Short Interest Increase?
Via Benzinga
My 3 Top Biotech Stock Picks for 2023
Via The Motley Fool
Stocks Drop On November 17 As The Dollar Moves Higher
Via Talk Markets
Why Emergent Bio Is Leading A Biotech Bloodbath — With Xenon Pharma Trailing
Via Investor's Business Daily
2 Healthcare Stocks Poised to Rocket Higher in the 4th Quarter
Via The Motley Fool
What To Watch In The S&P Biotech ETF After Johnson & Johnson's $16.6B Abiomed Deal
Via Benzinga
Can Biotech Stocks Continue Rallying In This Bear Market?
Via Talk Markets
This Beaten-Down ETF Is Still a Screaming Bear-Market Buy
Via The Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
B. Riley Financial's diverse suite of services goes beyond traditional financial service offerings. By leveraging cross-platform expertise and assets, B. Riley Financial companies are uniquely positioned to provide full service, collaborative solutions to our clients at every stage of the business life cycle and in all market conditions.

B. Riley refers to B. Riley Financial, Inc. and/or one or more of its subsidiaries or affiliates. Click here for further details.